Abstract
Cetuximab (Erbitux®) is a monoclonal antibody specifically bound to Human Epidermal Growth Factor Receptor (EGFR) that produces an antitumor effect by blocking the signaling pathway via EGFR in tumor cells. We examined four cases involving the administration of Cetuximab for recurrent head and neck cancer treated at our hospital. The results indicated a 50% response rate in terms of effectiveness. As to adverse events, we noted leukopenia and skin disorders, which were successfully treated conservatively. It is therefore necessary to make appropriate preparations for infusion reactions in the case of an emergency.
